- Home
- IPHA vs GNLX Comparison
IPHA vs GNLX Comparison
Compare IPHA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- GNLX
- Stock Information
- Founded
- IPHA 1999
- GNLX 2001
- Country
- IPHA France
- GNLX United States
- Employees
- IPHA N/A
- GNLX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- GNLX Health Care
- Exchange
- IPHA Nasdaq
- GNLX Nasdaq
- Market Cap
- IPHA 160.1M
- GNLX 184.4M
- IPO Year
- IPHA 2019
- GNLX 2023
- Fundamental
- Price
- IPHA $2.34
- GNLX $2.91
- Analyst Decision
- IPHA Strong Buy
- GNLX Strong Buy
- Analyst Count
- IPHA 1
- GNLX 4
- Target Price
- IPHA $11.00
- GNLX $17.75
- AVG Volume (30 Days)
- IPHA 31.8K
- GNLX 148.2K
- Earning Date
- IPHA 03-27-2025
- GNLX 05-06-2025
- Dividend Yield
- IPHA N/A
- GNLX N/A
- EPS Growth
- IPHA N/A
- GNLX N/A
- EPS
- IPHA N/A
- GNLX N/A
- Revenue
- IPHA $20,831,349.00
- GNLX N/A
- Revenue This Year
- IPHA $209.83
- GNLX N/A
- Revenue Next Year
- IPHA $83.96
- GNLX N/A
- P/E Ratio
- IPHA N/A
- GNLX N/A
- Revenue Growth
- IPHA N/A
- GNLX N/A
- 52 Week Low
- IPHA $1.29
- GNLX $1.60
- 52 Week High
- IPHA $3.51
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- IPHA 67.63
- GNLX 53.28
- Support Level
- IPHA $2.22
- GNLX $2.26
- Resistance Level
- IPHA $2.45
- GNLX $3.06
- Average True Range (ATR)
- IPHA 0.14
- GNLX 0.29
- MACD
- IPHA 0.03
- GNLX 0.04
- Stochastic Oscillator
- IPHA 82.52
- GNLX 72.86
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.